FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: July 25, 2018
A breath test for early-stage Parkinson’s
“Sensor Array for Detection of Early Stage Parkinson’s Disease before Medication”
ACS Chemical Neuroscience
Symptoms of Parkinson’s disease include tremor, loss of smell and neuropsychiatric problems. However, many people aren’t diagnosed until their disease is well-advanced, which could limit their treatment options. Now, researchers have tested a sensor to detect early-stage Parkinson’s disease from the breath of patients. They report their results in ACS Chemical Neuroscience.
According to the Parkinson’s Foundation, about 60,000 Americans are diagnosed with the movement disorder each year. But by the time most people experience symptoms, they have already lost many of the dopamine-producing neurons affected by the disease. Diagnosing Parkinson’s at an earlier stage, for example, at a routine doctor’s visit, could help these patients begin neuroprotective therapy sooner. To this end, John P.M. Finberg, Hossam Haick and their colleagues previously developed a device with an array of 40 sensors based on gold nanoparticles or single-walled carbon nanotubes. Each sensor had a different chemical attached that could bind certain volatile molecules in the breath, and this binding changed the electrical resistance of the sensor. The device detected differences in the exhaled breath of people already being treated for Parkinson’s disease and healthy controls. Now, they wanted to see if the device could detect differences in the breath of patients with early-stage, not-yet-treated Parkinson’s disease.
The researchers tested the device on the exhaled breath of 29 newly diagnosed patients who had not yet begun taking medication for their illness. When comparing the sensor output to that of 19 control subjects of similar age, they found that the array detected early Parkinson’s disease with 79 percent sensitivity, 84 percent specificity and 81 percent accuracy, which was better than a diagnostic smell test and almost as good as an ultrasound scan of the brain. Although the device needs to be improved and validated by larger studies, the researchers say that it has potential as a small, portable system to screen at-risk individuals without the need for highly trained specialists.
The authors acknowledge funding from the Israeli Ministry of Economy and Industry and the Britain Israel Research and Academic Exchange Partnership.
Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.